24-hour IOP-lowering Effect of Brimonidine 0.1%
Information source: Allergan
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Open-angle Glaucoma; Ocular Hypertension
Intervention: brimonidine 0.1% (Alphagan® P) (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Allergan Official(s) and/or principal investigator(s):
Medical Affairs, Study Director, Affiliation: Allergan
Summary
This study will evaluate the efficacy and safety of brimonidine 0. 1% three-times daily in
patients with glaucoma or ocular hypertension
Clinical Details
Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Intraocular Pressure (IOP) for a 24-Hour Period at Week 4
Secondary outcome: Change From Baseline in Intraocular Pressure (IOP) for a 24-Hour Period at Week 4Ocular Perfusion Pressure (OPP) for a 24-Hour Period at Week 4 Change in Ocular Perfusion Pressure (OPP) Over a 24-Hour Period at Week 4
Eligibility
Minimum age: 40 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- patients with open-angle glaucoma or ocular hypertension
Exclusion Criteria:
- allergy to brimonidine
- inability to complete 24 hour stay for monitoring
Locations and Contacts
San Diego, California, United States
Additional Information
Starting date: December 2006
Last updated: October 18, 2011
|
